Notícias

Keros Therapeutics Authorizes Additional $5 Mln Share Repurchase Program

NASDAQ

(RTTNews) - Keros Therapeutics, Inc. (KROS), a clinical-stage biopharmaceutical company, on Monday announced that its board of directors has approved an additional $5 million share repurchase program.

Ler o briefing completo da Veytics

Mostramos publicamente o ponto principal. Crie uma conta gratuita para continuar lendo o artigo completo, salva-lo, comenta-lo e conecta-lo ao contexto de mercado e OSINT.